Health Care News – Read More Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, the list price for Wegovy, Ozempic and Rybelsus, Novo’s semaglutide products, will be $675 across the board in the U.S. This reduction…
Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus
HootMD curates medical news from trusted publishers. Follow the links in this article to read the full story at the original source.
